NMPS-- Biotech-- Cancer Screening -- New Way To Use NMP Test for Early Detection of Cervical PreMalignancies.
I did not see this new potential usage for NMPS's Nuclear Protein Matrix screening technique as the next development in the NMPS story. But it is a positive one.
NMPS could end up with a very Large revenue stream if their products can be used for so many cancer screenings.
John
------------------------------------
PRECLINICAL STUDY REPORTS MATRITECH'S NMP179(TM) 'MAY BE AN EFFECTIVE MARKER FOR THE EARLY DETECTION' OF CERVICAL PREMALIGNANCIES FINDINGS reported in the November-December issue of Acta Cytologica "NMP179 showed high sensitivity for the detection of precancer, especially with regard to advanced cases(96.7%). This is significant since these are the preneoplastic lesions most likely to progress to invasive cancer." Martha Hutchinson, Ph.D., M.D. Director of Cytopathology Women and Infants' Hospital, Providence, R.I.
PR NEWSWIRE - December 03, 1999 07:59
NEWTON, Mass., Dec 3, 1999 /PRNewswire via COMTEX/ -- Matritech Inc. (Nasdaq: NMPS), a company specializing in products designed to detect, manage and screen cancer, announced today that a pre-clinical study reported in the November-December 1999 issue of Acta Cytologica reported that its cervical cancer test, NMP179(TM), was reliable and highly accurate in detecting pre-invasive lesions that could progress to cervical cancer.
The blinded study by Brigham and Women's Hospital (Boston, Mass.) and Women and Infants' Hospital (Providence, R.I.) evaluated 261 cervical cytology specimens. NMP179 detected 96.7 percent of cases diagnosed as high-grae squamous intraepithelial lesions (HSIL).
"We are encouraged by the clinical performance of NMP179 in the early identification of women at high risk of developing cervical cancer," said David L. Corbet, President and Chief Operating Officer of Matritech. "Acta Cytologica is among the preeminent peer-reviewed journals in the field of cytology. The report of NMP179's performance in a journal of this stature is further confirmation of the clinical potential of this NMP-based product.
"According to the American Cancer Society, cervical cancer will kill 4, 800 women this year. The potential early predictive value of NMP179 offers new hope in the fight against the disease because, according to the International Federation of Gynecology and Obstetrics, the survival rate for cervical cancer is 91 percent when discovered in early stages," Corbet continued.
The data from the study published in Acta Cytologica support the recent findings from a subsequent investigation of NMP179. In a separate pilot study presented in late 1998 at the annual meeting of the American Society of Cytopathology, physicians at New England Medical Center in Boston, as well as scientists at Matritech, reported that the NMP179 test identified 100 percent of atypical Pap smears that contained both hidden high-grade precancerous lesions (HSIL), as well as those that would later progress to HSIL
Matritech Inc., based in Newton, Mass., is using its proprietary nuclear matrix protein (NMP) technology, discovered at the Massachusetts Institute of Technology and licensed exclusively to Matritech, to develop and commercialize innovative serum-, cell- and urine-based NMP diagnostics that enable physicians to reliably detect and monitor the presence of bladder, colon, cervical, breast and prostate cancers. Matritech's nuclear matrix protein (NMP) technology platform correlates levels of NMPs in body fluids and tissues to the presence of cancer. Multiple published clinical studies have validated this ability of NMPs to detect early-stage cancerous abnormalities. Matritech has a deep pipeline of NMP-based products in pre-clinical and clinical development
SOURCE Matritech Inc. (C) 1999 PR Newswire. All rights reserved. prnewswire.com -0- CONTACT: Stephen D. Chubb, CEO or David L. Corbet, President of
Matritech, Inc., 617-928-0820 or Derek Caldwell, Investor Relations of
Sunrise Financial Group, 212-421-1616 or Steve Danehy, Media Relations of Ronald Trahan Associates, Inc., 617-332-0101
WEB PAGE: matritech.com
GEOGRAPHY: Massachusetts
/
------------------------------------------------------------ |
